Fred Middleton, M.B.A.
Fred Middleton has over thirty years of experience in the biotechnology and biomedical industries in both corporate operating management and as an institutional venture capital investor. At Sanderling, he has worked as an investor, management team member and director in over 20 new biomedical ventures built in Sanderling’s venture investment portfolios since 1988. Recently, he Read More »Read More »
Timothy Mills, Ph.D.
Timothy C. Mills has over twenty-five years of experience in venture capital investing, corporate management, product development and biomedical research. Dr. Mills has participated in 20+ companies in both investor and operating roles in the areas of: Biotherapeutics, Medical Technology and i-Health. Dr. Mills joined Sanderling as an Operating Partner in July 1998, was promoted Read More »Read More »
Michael Dixon, C.P.A.
Michael Dixon, CPA CA has over 18 years of experience working in an executive role for venture-backed companies. As CEO of Therillia Development Company Inc., Mr. Dixon oversees the development of therapeutic assets of interest to Therillia’s shareholders, including dalcetrapib. Prior to his role in Therillia, Mr. Dixon was Chief Financial Officer of Gemin X Pharmaceuticals. At Read More »Read More »
Timothy Wollaeger, M.B.A.
Managing Director Emeritus
Timothy Wollaeger has more than forty years’ experience in the medical products and biotechnology fields in both corporate management and venture capital. Mr. Wollaeger joined Sanderling Ventures as a Managing Director in 2002, and opened the firm’s San Diego office. Mr. Wollaeger serves on the Board of Directors for several Sanderling portfolio companies, including CalciMedica Read More »Read More »
Pierre Beauparlant, Ph.D, has more than 25 years of experience in large pharma and development stage, venture backed biopharmaceutical companies with expertise from discovery through commercialization. Dr. Beauparlant has served as CEO of companies of the Sanderling portfolio, including PreciThera Inc. an early-stage company specialized in developing biologics for rare musculoskeletal diseases and SpecificiT Pharma Inc. Read More »Read More »
Peter McWilliams, Ph.D. & M.B.A.
Dr. McWilliams is the Chief Business Officer of Glycomine, a company developing orphan drugs for serious rare disorders of metabolism and protein misfolding. He was previously a Managing Director at Sanderling Ventures where he was responsible for its investment in Actimis Pharmaceuticals and, as CEO, led the company into the clinic and through to a Read More »Read More »
Benjamin McGraw III, Pharm.D.
Benjamin F. McGraw, III, is the Executive Chairman and CEO of TheraVida, Inc., a private biotechnology company, Managing Member of Long Shadows Asset Management, LLC and CEO of Auration Biotech, Inc., a private biotechnology company. He was previously Chairman and CEO of Valentis, Inc., a public biotechnology company. Prior to this, Doctor McGraw was Corporate Read More »Read More »
Paulette Taylor. J.D.
General Counsel & Principal
Paulette Taylor is of counsel to Sanderling after being employed by Sanderling from December, 1996 until February, 2015. She acts as legal counsel to Sanderling and certain Sanderling Portfolio Companies. Prior to Ms. Taylor’s association with Sanderling, she was Counsel for Alumax Inc. from 1975-1989 and had extensive domestic and international corporate legal responsibilities. From Read More »Read More »
Robert G. McNeil, Ph.D.
Founding Partner (September 4, 1943 – July 23, 2021)
Robert McNeil founded Sanderling Ventures in 1979 and had served since then as a Managing Director of Sanderling’s seven investment partnerships. Dr. McNeil had been the seed investor for many successful companies including Western Technology Ventures, Advanced Cardiovascular Systems (acquired by Eli Lilly and spun out as Guidant Corp.) and Ventritex (acquired by St. Jude Read More »Read More »